Extended Data Figure 7: FOXO1_OE CAR T cells demonstrate enhanced anti-tumor activity in vivo.

a,b, A curative dose of 2×10⁶ tNGFR-purified CD19.BBζ CAR T cells overexpressing tNGFR (black), TCF1 (red), FOXO1 (blue), or FOXO1_3A (orange) were infused into Nalm6 leukemia-bearing mice 7 days post-engraftment. a, Experimental schematic (top) and tumor bioluminescence of multiple timepoints from 1 representative donor (bottom) (n = 3–5 mice per group). b, Combined tumor bioluminescence data from 2 donors at day 42–45 (n = 3–10 mice per group; 1 donor for FOXO1_3A). c, Tumor bioluminescence data for Nalm6-bearing mice injected with a curative dose of 2×10⁶ CD19.28ζ CAR T cells outlined in Figure 5b. d, CD19.28ζ CAR and tNGFR expression on circulating human CD45+ cells on day 21 post-CAR T infusion. These data show one representative mouse from each group and corresponds to Figures 5b–d. b, Mann-Whitney test. c, 2-way ANOVA with Dunnett’s multiple comparisons test. *, P < 0.05; **, P < 0.01; ns, P > 0.05.